Importance Continuing molecularly targeted treatment beyond disease progression in non–small-cell
lung cancer (NSCLC) has appeared promising in retrospective analyses, …

… In the BR.21 study, treatment with erlotinib was associated with … study was an open-label,
phase IV study with erlotinib … ; this study was designed to provide access to erlotinib in the …

… This study suggested that higher CSF concentration could be achieved with erlotinib and
that erlotinib could be more effective for the treatment for CNS metastases, especially …

… The primary objective of this study was to characterize the pharmacokinetics of erlotinib in
a large number of patients with solid tumors and identify covariates that have an impact on its …

… of erlotinib with standard chemotherapy could enhance survival in chemotherapy-naïve
patients with advanced or metastatic non–small-cell lung cancer (… in this study and erlotinib. …

… Patients who discontinued erlotinib received no further study treatment. Subsequent therapy
was provided at the treating doctor's discretion. All patients were followed-up for survival …

… study to demonstrate a survival benefit for this class of compound in non-small cell lung
cancer. The future role of … Phase II studies of gefitinib or erlotinib in non-small cell lung cancer. …

… and good tolerability in non-small cell lung cancer (NSCLC). In particular, … study conducted
by the Korean Cancer Study Group was to evaluate the efficacy and tolerability of erlotinib …

… QoL and symptom data in this analysis were also similar to the overall study population, with
no erlotinib-related QoL impairment. In the SD group, the HRs were time to deterioration of …

… In our study, erlotinib treatment consistently resulted in a time-dependent reduction of p27
KIP1 phosphorylation at Thr187 and decrease in SKP2 levels. Overall, our findings suggest …